SCHEMBL23364360

SCHEMBL23364360

COC(=O)C1=CC(=O)C=CC1C(=O)OC

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SETD7 Q8WTS6 2/20 0.36
ALDH1A1 P00352 3/20 0.33
DNTT P04053 1/20 0.32
KDM4E B2RXH2 2/20 0.32
GLA P06280 2/20 0.32
GAA P10253 2/20 0.32
HPGD P15428 2/20 0.32
CASP1 P29466 2/20 0.32
CASP7 P55210 2/20 0.32
HSD17B10 Q99714 2/20 0.32
ATM Q13315 1/20 0.32
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
RCE1 Q9Y256 1/20 0.31
POLB P06746 1/20 0.31
KCNH2 Q12809 1/20 0.31
MAPT P10636 1/20 0.31
TSHR P16473 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL818072 0.76 TDP1 (0.32) ALDH1A1KDM4EGLAGAAHPGD
SCHEMBL818893 0.75 TDP1 (0.31) ALDH1A1MEN1KMT2AMAPTSMN1; SMN2
SCHEMBL818870 0.71 KDM4E (0.32) ALDH1A1KDM4EGLAGAAHPGD
SCHEMBL28275195 0.69 LMNA (0.30) TSHR
SCHEMBL11076557 0.69 DNTT (0.37) SETD7ALDH1A1DNTTCASP1HSD17B10
SCHEMBL7035623 0.67 DNTT (0.36) SETD7ALDH1A1DNTTKMT2APOLB
SCHEMBL28067834 0.66
SCHEMBL20383513 0.66 ALDH1A1 (0.47) ALDH1A1KDM4EGAAHPGDCASP1
SCHEMBL2834961 0.66 ALDH1A1 (0.47) ALDH1A1KDM4EGAAHPGDCASP1
SCHEMBL7929530 0.64 DNTT (0.37) ALDH1A1DNTTHSD17B10POLBTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12377152-B2 Compounds for degrading alpha-synuclein aggregates and uses thereof APRINOIA THERAPEUTICS LIMITED (CN) 2025-08-05 US disclosed
US-20230346955-A1 COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF APRINOIA THERAPEUTICS LIMITED (CN) 2023-11-02 US disclosed
US-20220354835-A1 COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF APRINOIA THERAPEUTICS LIMITED (CN) 2022-11-10 US disclosed
EP-4058065-A1 COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF Aprinoia Therapeutics Limited (HK) 2022-09-21 EP disclosed
US-20220280650-A1 COMPOUNDS FOR DEGRADING ALPHA-SYNUCLEIN AGGREGATES AND USES THEREOF APRINOIA THERAPEUTICS LIMITED (CN) 2022-09-08 US disclosed
US-11291732-B1 Compounds for degrading α-synuclein aggregates and uses thereof APRINOIA THERAPEUTICS LIMITED (HK) 2022-04-05 US disclosed
WO-2021097243-A1 COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF APRINOIA THERAPEUTICS INC. (CN) 2021-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220280650-A1 COMPOUNDS FOR DEGRADING ALPHA-SYNUCLEIN AGGREGATES AND USES THEREOF SNCA, PARK7, PRNP SETD7 4401/4885ALDH1A1 2065/4885DNTT 2495/4885
US-12377152-B2 Compounds for degrading alpha-synuclein aggregates and uses thereof SNCA, PARK7, PRNP SETD7 4401/4885ALDH1A1 2065/4885DNTT 2495/4885
US-20230346955-A1 COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF MAPT, PRNP, APP SETD7 3923/4885ALDH1A1 1759/4885DNTT 1790/4885
US-11291732-B1 Compounds for degrading α-synuclein aggregates and uses thereof SNCA, PARK7, PRNP SETD7 4276/4885ALDH1A1 2226/4885DNTT 2646/4885
US-20220354835-A1 COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF MAPT, PRNP, APP SETD7 3956/4885ALDH1A1 1847/4885DNTT 1787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.